Highlights of This Issue 773

REVIEWS

775 Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment
Zihao Liu, Andrew J. Sanders, Gehao Liang, Erwei Song, Wen G. Jiang, and Chang Gong

787 Nodal Signaling as a Developmental Therapeutics Target in Oncology
Aparna Kalyan, Benedito A. Carneiro, Sunandana Chandra, Jason Kaplan, Young Kwang Chae, Maria Matsangou, Mary J.C. Hendrix, and Francis Giles

SMALL MOLECULE THERAPEUTICS

793 Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
Suman Chatterjee, Eric H.-B. Huang, Ian Christie, Brenda F. Kurland, and Timothy F. Burns

805 Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer

819 Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
Zhanjun Hou, Leda Gattoc, Carrie O’Connor, Si Yang, Adrienne Wallace-Povilko, Christina George, Steve Orr, Lisa Polin, Kathryn White, Juwanna Kushner, Robert T. Morris, Aleem Gangjee, and Larry H. Matherly

LARGE MOLECULE THERAPEUTICS

838 Synthesis and Evaluation of the Novel Prostamide, 15-Deoxy, Δ12,14-Prostamide J2, as a Selective Antitumor Therapeutic
Daniel A. Ladin, Eman Soliman, Rene Escobedo, Timothy L. Fitzgerald, Li V. Yang, Colin Burns, and Rukiyah Van Dross

850 Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

861 Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Elena Burova, Aynur Hermann, Janelle Waite, Terra Potocky, Verus Lai, Seongwon Hong, Matt Liu, Omaiz Albritton, Amy Woodruff, Qi Wu, Amanda D’Orvilliers, Elena Garnova, Ashique Rafique, William Poueymirou, Joel Martin, Tammy Huang, Dimitris Skokos, Joel Kantrowitz, Jon Popke, Markus Molina, Douglas MacDonald, Ella Lofe, William Olson, Israel Lowy, Andrew Murphy, and Gavin Thurston

871 Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

831 Fluorinated N,N’-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells
Dasha E. Kenlan, Piotr Rybakhou, Vitaliy M. Sviriipa, Heidi L. Weiss, Chunming Liu, David S. Watt, and B. Mark Evers
### Table of Contents

**Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation**
Nikolas Stefan, Rémy Gebéux, Lorenz Waldmeier, Tamara Hell, Marie Escher, Fabian I. Wolter, Ulf Grawunder, and Roger R. Beerli

**Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer**
Jörg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Beatrix Stelte-Ludwig, Carol Pena, Claudia Lange, Sven Golffier, Christoph Kneip, Patricia E. Carrigan, Kirk Mclean, Jennifer N. Fornace, Jürgen Muller, Michael S. Henson, Matthew Breen, Kerstin Lindblad-Toh, Felix Oh, Kristy Pilbeam, Jaime F. Modiano, and Daniel A. Vallera

**Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth**

**Inhibition of Isoprenylcysteine Carboxymethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer**
Kanjoormana Aryan Manu, Tin Fan Chai, Jing Tsong Teh, Wan Long Zhu, Patrick J. Casey, and Mei Wang

**Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145**
Guosong Jiang, Chao Huang, Jingxia Li, Haishan Huang, Honglei Jin, Junlan Zhu, Xue-Ru Wu, and Chuanshu Huang

**Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma**
Fumihito Noguchi, Shigeki Inui, Clare Fedele, Mark Shackleton, and Satoshi Itami

**Cancer Biology and Signal Transduction**

**COMPANION DIAGNOSTICS AND CANCER BIOMARKERS**

**Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology**
Hatim Husain, David Nykin, Nam Bui, Daniel Quan, German Gomez, Brian Woodward, Sumathi Venkatapathy, Radha Duttagupta, Eric Fung, Scott M. Lippman, and Razelle Kurzrock

**MODELS AND TECHNOLOGIES**

**Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR**

**HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer**
Karem A. Court, Hiroto Hatakeyama, Sherry Y. Wu, Mangala S. Lingegowda, Cristian Rodriguez-Aguayo, Gabriel López-Berestein, Lee Ju-Seog, Carlos Rinaldi, Eduardo J. Juan, Anil K. Sood, and Madeline Torres-Lugo

**RETRACTION**

**Retraction: Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs**

---

**For more information please visit** [www.aacrjournals.org](http://www.aacrjournals.org)
ABOUT THE COVER

The cover shows the whole genome evaluation of copy number alterations ordered sequentially by chromosomes and represented by different colors. A patient with metastatic lung cancer was found to have very high amplification of EGFR (copy number = 15) and HFN1B (copy number = 11) detected by the cell free DNA obtained from ascites. The results indicate that cell free DNA from ascites and pleural effusions may provide additional data complementing tumor and plasma cell-free DNA molecular characterization, and a context for important insights into clonal dynamic change within primary tumor and metastatic deposits.